[1] LECHLEITNER M, ABRAHAMIAN H, FRANCESCONI C, et al. Diabetische Neuropathie und diabetischer Fuß (Update 2019) [Diabetic neuropathy and diabetic foot syndrome (Update 2019)]. Wien Klin Wochenschr. 2019;131(Suppl 1):141-150.
[2] YAZDANPANAH L, SHAHBAZIAN H, NAZARI I, et al. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018; 2018:7631659.
[3] 王江宁, 高磊.糖尿病足慢性创面治疗的新进展[J].中国修复重建外科杂志,2018,32(7):832-837
[4] ZELEN CM, ORGILL DP, SERENA TE, et al. An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: A prospective, randomised, controlled, multicentre follow-up trial. Int Wound J. 2018;15(5):731-739.
[5] SARKOZYOVA N, DRAGUNOVA J, BUKOVCAN P, et al. Preparation and processing of human allogenic dermal matrix for utilization in reconstructive surgical procedures. Bratisl Lek Listy. 2020;121(6):386-394.
[6] 郭海雷,凌翔伟,刘政军,等.刃厚头皮与异体脱细胞真皮基质复合移植修复特大面积烧伤患者手部深度创面[J].中华烧伤杂志, 2019,35(12):876-878.
[7] WEAVER ML, HICKS CW, CANNER JK, et al. The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system predicts wound healing better than direct angiosome perfusion in diabetic foot wounds. J Vasc Surg. 2018;68(5):1473-1481.
[8] 柯昌能,刘坡,陈杰明,等.脱细胞同种异体真皮与自体刃厚皮复合移植烧伤功能部位修复创面[J].中国组织工程研究,2015, 19(29):4652-4656.
[9] BORDIANU A, BOBIRCĂ F, PĂTRAŞCU T. Skin Grafting in the Treatment of Diabetic Foot Soft Tissue Defects. Chirurgia (Bucur). 2018;113(5):644-650.
[10] 薛春利,胡志成,杨祖贤,等.异体脱细胞真皮基质治疗糖尿病足溃疡临床效果荟萃分析[J].中华烧伤杂志,2016,32(12):725-729.
[11] SANNIEC K, NGUYEN T, VAN ASTEN S,et al. Split-Thickness Skin Grafts to the Foot and Ankle of Diabetic Patients. J Am Podiatr Med Assoc. 2017;107(5):365-368.
[12] ZELEN CM, ORGILL DP, SERENA T, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J. 2017;14(2):307-315.
[13] CAMPITIELLO F, MANCONE M, DELLA CORTE A,et al. To evaluate the efficacy of an acellular flowable matrix in comparison with a wet dressing for the treatment of patients with diabetic foot ulcers: a randomized clinical trial. Updates Surg. 2017;69(4):523-529.
[14] WIDJAJA W, TAN J, MAITZ PKM. Efficacy of dermal substitute on deep dermal to full thickness burn injury: a systematic review. ANZ J Surg. 2017;87(6):446-452.
[15] PIRAYESH A, HOEKSEMA H, RICHTERS C, et al. Glyaderm(®) dermal substitute: clinical application and long-term results in 55 patients. Burns. 2015;41(1):132-144.
[16] BOHAC M, VARGA I, POLAK S, et al. Delayed post mastectomy breast reconstructions with allogeneic acellular dermal matrix prepared by a new decellularizationmethod. Cell Tissue Bank. 2018;19(1):61-68.
[17] SPECHT M, KELM S, MIRASTSCHIJSKI U. Eignung biologischer azellulärer dermaler Matrices als Hautersatz [Suitability of biological acellular dermal matrices as a skin replacement]. Handchir Mikrochir Plast Chir. 2020;52(6):533-544.
[18] GOODARZI P, FALAHZADEH K, NEMATIZADEH M, et al. Tissue Engineered Skin Substitutes. Adv Exp Med Biol. 2018;1107:143-188.
[19] NITA M, PLISZCZYŃSKI J, KOWALEWSKI C, et al. New Treatment of Wound Healing With Allogenic Acellular Human Skin Graft: Preclinical Assessment and In Vitro Study. Transplant Proc. 2020;52(7):2204-2207.
[20] KUO S, KIM HM, WANG Z, et al. Comparison of two decellularized dermal equivalents. J Tissue Eng Regen Med. 2018;12(4):983-990.
[21] HUANG W, CHEN Y, WANG N, et al. The Efficacy and Safety of Acellular Matrix Therapy for Diabetic Foot Ulcers: A Meta-Analysis of Randomized Clinical Trials. J Diabetes Res. 2020;2020:6245758.
[22] DASGUPTA A, ORGILL D, GALIANO RD,et al. A Novel Reticular Dermal Graft Leverages Architectural and Biological Properties to Support Wound Repair. Plast Reconstr Surg Global Open. 2016;4(10):e1065.
[23] CHO H, BLATCHLEY MR, DUH EJ, et al. Acellular and cellular approaches to improve diabetic wound healing. Advanced Drug Delivery Reviews. 2019;146:267-288.
[24] AHMEDBEYLI C, IPCI SD, CAKAR G, et al. Laterally positioned flap along with acellular dermal matrix graft in the management of maxillary localized recessions. Clin Oral Investig. 2019;23(2):595-601.
[25] KUO KC, LIN RZ, TIEN HW, et al. Bioengineering vascularized tissue constructs using an injectable cell-laden enzymatically crosslinked collagen hydrogel derived from dermal extracellular matrix. Acta Biomater. 2015;27:151-166.
[26] WOOD BC, MANTILLA-RIVAS E, GOLDRICH A, et al. Correction of Microstomia Reconstruction with the Use of Acellular Dermal Matrix for Buccal Reconstruction. J Craniofac Surg. 2019;30(3):736-738.
[27] YANG Z, WU X, CHEN C, et al. Comparison of type I tympanoplasty with acellular dermal allograft and cartilage perichondrium. Acta Oto-Laryngol. 139:10:833-836.
[28] HU Z, ZHU J, CAO X, et al. Composite Skin Grafting with Human Acellular Dermal Matrix Scaffold for Treatment of Diabetic Foot Ulcers: A Randomized Controlled Trial. J Am Coll Surg. 2016;222(6):1171-1179.
[29] CAZZELL S, VAYSER D, PHAM H, et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair Regen. 2017;25(3): 483-497.
[30] ZELEN CM, ORGILL DP, SERENA TE, et al. Human Reticular Acellular Dermal Matrix in the Healing of Chronic Diabetic Foot Ulcerations that Failed Standard Conservative Treatment: A Retrospective Crossover Study. Wounds. 2017;29(2):39-45.
[31] LEE M, JUN D, CHOI H, et al. Clinical Efficacy of Acellular Dermal Matrix Paste in Treating Diabetic Foot Ulcers. Wounds. 2020;32(1):50-56.
[32] CAZZELL S. A Randomized Controlled Trial Comparing a Human Acellular Dermal Matrix Versus Conventional Care for the Treatment of Venous Leg Ulcers. Wounds. 2019;31(3):68-74.
[33] LUTHRINGER M, MUKHERJEE T, ARGUELLO-ANGARITA M, et al. Human-derived Acellular Dermal Matrix Grafts for Treatment of Diabetic Foot Ulcers: A Systematic Review and Meta-analysis. Wounds. 2020;32(2):57-65.
[34] KIM YH, HWANG KT, KIM KH,et al. Application of acellular human dermis and skin grafts for lower extremity reconstruction. J Wound Care. 2019;28(Sup4):S12-S17.
[35] ÁLVARO-AFONSO FJ, GARCÍA-ÁLVAREZ Y, LÁZARO-MARTÍNEZ JL,et al. Advances in Dermoepidermal Skin Substitutes for Diabetic Foot Ulcers. Curr Vasc Pharmacol. 2020;18(2):182-192.
[36] TCHERO H, HERLIN C, BEKARA F, et al. Failure rates of artificial dermis products in treatment of diabetic foot ulcer: A systematic review and network meta-analysis. Wound Repair Regen. 2017;25(4):691-696.
[37] WALTERS J, CAZZELL S, PHAM H,et al. Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix Versus Conventional Care Wound Management and an Active Comparator in the Treatment of Full-Thickness Diabetic Foot Ulcers. Eplasty. 2016;16:e10.
[38] TOGNETTI L, PIANIGIANI E, IERARDI F, et al. The use of human acellular dermal matrices in advanced wound healing and surgical procedures: State of the art. Dermatol Ther. 2021;34(4):e14987.
[39] JEON H, KIM J, YEO H, et al. Treatment of diabetic foot ulcer using matriderm in comparison with a skin graft. Arch Plast Surg. 2013;40(4): 403-408.
[40] TCHANQUE-FOSSUO CN, DAHLE SE, LEV-TOV H, et al. Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: Interim results of a comparative efficacy randomized controlled trial. J Tissue Eng Regen Med. 2019;13(8):1430-1437.
|